Aktie A2DW3Q MERRIMACK PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Merrimack Pharmaceuticals, Inc.

Aktien

A2DW3Q

US5903282094

MACK

Realtime-Estimate Cboe BZX
Andere Börsenplätze
 17:37:52 01.05.2024 		% 5 Tage % 1. Jan.
14,95 USD +1,42 % Intraday Chart für Merrimack Pharmaceuticals, Inc. +1,56 % +11,41 %
27.03. Merrimack erhält $225 Millionen Meilensteinzahlung und setzt Treffen für Auflösungsplan an MT
07.03. Merrimack Pharmaceuticals, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
Merrimack Receives $225 Million Milestone Payment from Ipsen
Merrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing
Merrimack Reports Third Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index
Insider Buy: Merrimack Pharmaceuticals
Merrimack Reports Second Quarter 2023 Financial Results
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Growth Index
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Completeness Index
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2500 Index
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000 Index
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DW3Q Aktie
  4. Nachrichten Merrimack Pharmaceuticals, Inc.
  5. Andere Sprachen